NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Results of Operations and Financial Condition
Item 2.02 below.

Item 2.02 Results of Operations and Financial Conditions.

On May 10, 2017, Nabriva Therapeutics AG (the “Company”) filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (the “Form 10-Q”). Immediately after the filing of the Form 10-Q, the Company furnished a Current Report on Form 8-K (the “Form 8-K”) disclosing that it had issued a press release announcing its consolidated financial results for the quarter ended March 31, 2017 and including a copy of the press release as an exhibit to the Form 8-K. The Company is furnishing this amendment on Form 8-K/A to the Form 8-K to reflect the correction of inadvertent discrepancies in the financial information disclosed in the tables at the end of the press release as compared to the financial information that was contained in the Form 10-Q. The discrepancies in the press release required a correction of total “Net cash used in operating activities” in the Consolidated Statement of Cash Flows for the three months ended March 31, 2016 and March 31, 2017 (although the components of this total amount were accurately stated in the press release). A copy of the corrected press release is included as Exhibit 99.1 to this Current Report on Form 8-K/A.

The information in this Form 8-K/A, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

Exhibit 99.1  Corrected press release issued by Nabriva Therapeutics AG, dated May 12, 2017.


About NABRIVA THERAPEUTICS AG (NASDAQ:NBRV)

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH.

NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Recent Trading Information

NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) closed its last trading session up +0.13 at 9.88 with 7,168 shares trading hands.